These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3263656)

  • 1. Advances in management of disseminated renal cell carcinoma.
    Javadpour N
    Prog Clin Biol Res; 1988; 277():85-91. PubMed ID: 3263656
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of interleukin-2 alone in disseminated renal cell carcinoma: an update.
    Javadpour N; Lalehzarian M
    Prog Clin Biol Res; 1989; 303():671-9. PubMed ID: 2789391
    [No Abstract]   [Full Text] [Related]  

  • 3. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J; Kirchner H; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of renal cell carcinoma with systemic administration of intermediate doses of recombinant human interleukin-2 alone. Recombinant Human Interleukin-2 (S-6820) Research Group on Renal Cell Carcinoma.
    Aso Y; Tazaki H; Umeda T; Marumo K
    Prog Clin Biol Res; 1989; 303():681-8. PubMed ID: 2675018
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunotherapy of disseminated renal cell carcinoma.
    Javapour N
    Md Med J; 1989 Nov; 38(11):963. PubMed ID: 2586256
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bacteremia caused by Streptococcus equisimilis in a neoplastic patient treated with recombinant interleukin 2].
    Pedro-Botet ML; Ribelles Entrena N; Carrasco Miserachs I; Carles Galcerán J; Sabria-Leal M; Arnal J
    Enferm Infecc Microbiol Clin; 1990 Dec; 8(10):659-60. PubMed ID: 2098130
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA; Benyunes MC; Bianco JA; Fefer A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract]   [Full Text] [Related]  

  • 8. [Repetitive immuno-embolization of inoperative liver metastases of renal cell carcinoma. Method characterization and preliminary results].
    Pomer S; Brado M; Roeren T; Brkovic D; Wiesel M; Staehler G; Keilholz U
    Urologe A; 1996 Jul; 35(4):310-4. PubMed ID: 8928360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor effects of interleukin 2 against renal cell carcinoma. In vitro study and clinical application.
    Marumo K; Tazaki H
    Prog Clin Biol Res; 1990; 350():263-73. PubMed ID: 2117286
    [No Abstract]   [Full Text] [Related]  

  • 11. High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma.
    Parkinson DR; Sznol M
    Semin Oncol; 1995 Feb; 22(1):61-6. PubMed ID: 7855620
    [No Abstract]   [Full Text] [Related]  

  • 12. Adoptive cellular therapy of renal carcinoma.
    West WH
    Prog Clin Biol Res; 1989; 303():689-96. PubMed ID: 2789392
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
    Shulman KL; Stadler WM; Vogelzang NJ
    Urology; 1996 Feb; 47(2):194-7. PubMed ID: 8607232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunotherapeutic treatment for metastatic renal carcinoma].
    Hidalgo Pardo F; Gutiérrez Sanz-Gadea C; Rebassa Llull MJ; García Bueno JM; Mus Malleu A; Losada González GP; Ozonas Moragues M
    Actas Urol Esp; 1998 Jan; 22(1):29-33. PubMed ID: 9542189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European studies of interleukin-2 in metastatic renal cell carcinoma.
    Atzpodien J; Kirchner H; Hänninen EL; Körfer A; Fenner M; Menzel T; Deckert M; Franzke A; Jonas U; Poliwoda H
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):22-6. PubMed ID: 8284688
    [No Abstract]   [Full Text] [Related]  

  • 16. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2.
    Buter J; Sleijfer DT; van der Graaf WT; de Vries EG; Willemse PH; Mulder NH
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):16-21. PubMed ID: 8284687
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA; Pierce WC; Belldegrun A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy and metastic renal cell cancer.
    Buzio C; De Palma G; Caminiti C; Cattabiani MA; Manenti L
    Nephrol Dial Transplant; 1996 Sep; 11(9):1890. PubMed ID: 8918650
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2).
    Huland E; Heinzer H; Huland H
    Anticancer Res; 1999; 19(4A):2679-83. PubMed ID: 10470219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical contrast reactions associated with systemic interleukin-2 therapy.
    Fishman JE; Aberle DR; Moldawer NP; Belldegrun A; Figlin RA
    AJR Am J Roentgenol; 1991 Apr; 156(4):833-4. PubMed ID: 2003450
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.